Search Result

Results for "

MTA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Endogenous Metabolite (3) Histone Methyltransferase (20) Influenza Virus (1) Isotope-Labeled Compounds (1) Kinesin (1) Microtubule/Tubulin (3) Parasite (2) Reference Standards (2) Small Interfering RNA (siRNA) (7)
By Research Areas:	Cancer (25) Infection (1) Metabolic Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (3) siRNAs (7)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16938

5'-Methylthioadenosine 5+ Cited Publications 5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine	Endogenous Metabolite Apoptosis Parasite	Metabolic Disease Cancer
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .

HY-139611

Navlimetostat 3 Publications Verification MRTX-1719; BMS-986504	Histone Methyltransferase	Cancer
Navlimetostat is a potent, orally active, selective *PRMT5-MTA* complex inhibitor, with IC₅₀ of 3.6 and 20.5 nM for *PRMT5-MTA* and PRMT5. Navlimetostat binds to the *PRMT5-MTA* complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .

HY-153390

AMG-193	Histone Methyltransferase	Cancer
AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC₅₀=0.107 μM), thereby protecting normal cells with wild-type MTAP .

HY-156680

Vopimetostat TNG-462	Histone Methyltransferase	Cancer
TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers .

HY-173522

KIF2C-IN-1	Kinesin Microtubule/Tubulin	Cancer
KIF2C-IN-1 is a cell-penetrating, selective KIF2C inhibitor with fluorescent properties (E_x/E_m = 410/510 nm). KIF2C-IN-1 exhibits notable cytotoxicity and weak inhibitory effects on KIF2A/B. KIF2C-IN-1 prohibits the dissociation of KIF2C from microtubules. KIF2C-IN-1 inhibiting KIF2C reverses cross-resistance to microtubule-targeting agents. KIF2C-IN-1 reduces tumorigenesis in chemoresistant triple-negative breast cancer (TNBC) model in mice with the combination of Paclitaxel (HY-B0015) .

HY-138684

MRTX9768	Histone Methyltransferase	Cancer
MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-139611C

Navlimetostat hydrochloride 3 Publications Verification MRTX-1719 hydrochloride; BMS-986504 hydrochloride	Histone Methyltransferase	Cancer
Navlimetostat hydrochloride is a potent, orally active, selective *PRMT5-MTA* complex inhibitor, with IC₅₀s of 3.6 and 20.5 nM for *PRMT5-MTA* and PRMT5. Navlimetostat hydrochloride binds to the *PRMT5-MTA* complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .

HY-N0086R

N6-Methyladenosine (Standard) 1 Publications Verification 6-Methyladenosine (Standard); N-Methyladenosine (Standard)	Endogenous Metabolite Influenza Virus Reference Standards	Infection
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .

HY-139611B

(S)-Navlimetostat (S)-MRTX-1719; (S)-BMS-986504	Histone Methyltransferase	Cancer
(S)-Navlimetostat (example 16-7) is the S-enantiomer of Navlimetostat. (S)-Navlimetostat is a *PRMT5/MTA* complex inhibitor, with an IC₅₀ of 7070 nM .

HY-162783

AZ-PRMT5i-1	Histone Methyltransferase	Cancer
AZ-PRMT5i-1 (Compound 28) is an effective and orally active MTAP-selective PRMT5 inhibitor. AZ-PRMT5i-1 also demonstrates MTA cooperativity and exhibits both in vitro and in vivo antitumor activities, and can be used to study MTAP-deficient cancers .

HY-158143

AZD3470	Histone Methyltransferase Apoptosis	Cancer
AZD3470 is an orally active MTA-cooperative PRMT5 inhibitor, selective for MTAP-deficient tumors. AZD3470 induces cell cycle G₂/M phase alterations, DNA damage, apoptosis, and symmetric dimethylarginine reduction. AZD3470 alters alternative splicing, increases skipped exon events in DNA repair and cell cycle pathways, and inhibits cancer cell proliferation and tumor growth. AZD3470 can be used for the research of non-small cell lung cancer and MTAP-deleted solid tumors .

HY-174983

*PRMT5-MTA-IN-6*	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-6 (Compound 31) is a selective *MTA*-cooperative PRMT5 inhibitor. PRMT5-MTA-IN-6 exhibits potent inhibitory activity against *PRMT5・MTA* (IC₅₀: 6.6 nM). PRMT5-MTA-IN-6 selectively inhibits the growth of MTAP-deleted HCT-116 cells (IC₅₀: 319 nM). PRMT5-MTA-IN-6 can be used in the research of MTAP-deleted tumors .

HY-176702

*PRMT5-MTA-IN-5*	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-5 (Compound 7) is an orally active, irreversible PRMT5-MTA complex (PRMT5•MTA) inhibitor (IC₅₀=1.15 nM). PRMT5-MTA-IN-5 blocks arginine methylation and inhibits ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-5 potently inhibits proliferation in MTAP-deficient tumor cells. PRMT5-MTA-IN-5 is promising for research of MTAP-deficient solid tumors, such as liver, breast, and pancreatic cancers .

HY-176701

*PRMT5-MTA-IN-4*	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC₅₀=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC₅₀=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .

HY-163737

ST-401	Microtubule/Tubulin	Cancer
ST-401, a microtubule-targeting agent (MTA), is a brain-penetrant microtubule (MT) assembly inhibitor. ST-401 disrupts microtubule (MT) function through gentle and reverisible reduction in MT assembly that triggers mitotic delay and cell death in interphase. ST-401 shows a potent antitumor activity .

HY-16938R

5'-Methylthioadenosine (Standard) 5'-(Methylthio)-5'-deoxyadenosine (Standard); 5'-Deoxy-5'-(methylthio)adenosine (Standard); 5'-S-Methyl-5'-thioadenosine (Standard)	Reference Standards Endogenous Metabolite Apoptosis Parasite	Metabolic Disease Cancer
5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].

HY-163799

*PRMT5-MTA-IN-1*	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-1 (Compound A9a) is an inhibitor for protein arginine methyltransferase *PRMT5-MTA. PRMT5-MTA-IN-1 inhibits the proliferation of colorectal cancer cell HCT116 wildtype and MTAP del mutant, with an IC₅₀* of 16 nM and 2.47 μM. PRMT5-MTA-IN-1 exhibits good liver microsomal stability and film permeability. PRMT5-MTA-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mice .

HY-162989

*PRMT5-MTA-IN-2*	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-2 (compund 1) is a MTA co-inhibitor of PRMT5 with IC₅₀ less than 1.5 nM .

HY-172733S

*PRMT5-MTA-IN-3-d3*	Isotope-Labeled Compounds Histone Methyltransferase	Cancer
PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active *PRMT5-MTA* inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

HY-RS08748

MTA3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MTA3 Human Pre-designed siRNA Set A contains three designed siRNAs for MTA3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MTA3 Human Pre-designed siRNA Set A MTA3 Human Pre-designed siRNA Set A

HY-RS08747

MTA2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MTA2 Human Pre-designed siRNA Set A contains three designed siRNAs for MTA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MTA2 Human Pre-designed siRNA Set A MTA2 Human Pre-designed siRNA Set A

HY-RS08746

MTA1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MTA1 Human Pre-designed siRNA Set A contains three designed siRNAs for MTA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MTA1 Human Pre-designed siRNA Set A MTA1 Human Pre-designed siRNA Set A

HY-RS19921

Mta1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mta1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mta1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mta1 Mouse Pre-designed siRNA Set A Mta1 Mouse Pre-designed siRNA Set A

HY-172733

*PRMT5-MTA-IN-3*	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective protein arginine methyltransferase 5 (PRMT5) inhibitor. PRMT5-MTA-IN-3 inhibits cell proliferation in the MTAP-deficient colorectal cancer HCT - 116 cell line with an IC₅₀ value of 5 nM. PRMT5-MTA-IN-3 is promising for research of cancers, especially for MTAP-deficient tumors, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer .

HY-138684A

MRTX9768 hydrochloride	Histone Methyltransferase	Cancer
MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-180816

*PRMT5-MTA-IN-7*	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-7 (Compound 14) is a selective *PRMT5-MTA* inhibitor. PRMT5-MTA-IN-7 exhibits K_D values of PRMT5-MTA-IN-7 for PRMT5-MTA and PRMT5-SAM of 236 nM and 2.84 μM respectively, and the IC₅₀ values of 4.08 and 13.6 μM respectively. PRMT5-MTA-IN-7 can selectively inhibit the proliferation of MTAP-deficient cancer cells. PRMT5-MTA-IN-7 can be used for the study of colon cancer .

HY-153390A

(R)-AMG-193	Histone Methyltransferase	Cancer
(R)-AMG-193 is an isomer of AMG 193 (HY-153390). AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC₅₀=0.107 μM), thereby protecting normal cells with wild-type MTAP .

HY-168842

PRMT5-IN-47	Histone Methyltransferase	Cancer
PRMT5-IN-47 (compound 20) is a potent, selectively and orally active, MTA cooperative PRMT5 inhibitor with an IC₅₀ value of 15 nM. PRMT5-IN-47 shows antiproliferative activity. PRMT5-IN-47 shows anticancer activity .

HY-178325

Tubulin-IN-57	Microtubule/Tubulin Apoptosis	Cancer
Tubulin-IN-57 is a Tubulin inhibitor. Tubulin-IN-57 is a potent antiproliferative agent that inhibits clonogenic formation, migration, and invasion of ovarian cancer cells. Tubulin-IN-57 inhibits tubulin polymerization, which in turn induces G2/M arrest and apoptosis in SKOV3 cells. Tubulin-IN-57 demonstrates potent antitumor activity without observable toxicity in an SKOV3 xenograft model. Y60S can be used for the study of ovarian cancer .

HY-181260

*PRMT5-MTA-IN-8*	Histone Methyltransferase Apoptosis	Cancer
PRMT5-MTA-IN-8 is an orally active *PRMT5-MTA* complex inhibitor (IC₅₀ = 4.4 nM). PRMT5-MTA-IN-8 inhibits the intracellular production of symmetric dimethylarginine (SDMA) as well as the proliferation of MTAP-deficient cells. PRMT5-MTA-IN-8 exerts antitumor efficacy by inhibiting PRMT5, reducing SDMA levels and inducing tumor cell apoptosis in mouse models of triple-negative breast cancer. PRMT5-MTA-IN-8 can be used in research related to cancers such as triple-negative breast cancer .

HY-RS27290

Mta2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mta2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mta2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mta2 Rat Pre-designed siRNA Set A Mta2 Rat Pre-designed siRNA Set A

HY-RS20776

Mta2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mta2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mta2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mta2 Mouse Pre-designed siRNA Set A Mta2 Mouse Pre-designed siRNA Set A

HY-RS26423

Mta1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mta1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mta1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mta1 Rat Pre-designed siRNA Set A Mta1 Rat Pre-designed siRNA Set A

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16938

5'-Methylthioadenosine 5+ Cited Publications 5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine	Natural Products Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Apoptosis Parasite
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .

HY-N0086R

N6-Methyladenosine (Standard) 1 Publications Verification 6-Methyladenosine (Standard); N-Methyladenosine (Standard)	Structural Classification Natural Products Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite Influenza Virus Reference Standards
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .

HY-16938R

5'-Methylthioadenosine (Standard) 5'-(Methylthio)-5'-deoxyadenosine (Standard); 5'-Deoxy-5'-(methylthio)adenosine (Standard); 5'-S-Methyl-5'-thioadenosine (Standard)	Structural Classification Natural Products Microorganisms Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Apoptosis Parasite
5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].

Species:	Human (2)
Tag:	GST (1) Flag (1)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702912

	METTL3 Protein, Human (sf9, FLAG) MTA70	Human	Sf9 insect cells
	METTL3 Protein, Human (sf9, FLAG) is the recombinant human-derived METTL3, expressed by Sf9 insect cells , with N-Flag labeled tag. ,

HY-P703029

	METTL3 Protein, Human (sf9, GST) MTA70	Human	Sf9 insect cells
	METTL3 Protein, Human (sf9, GST) is the recombinant human-derived METTL3, expressed by Sf9 insect cells , with GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-172733S

*PRMT5-MTA-IN-3-d3*
PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active *PRMT5-MTA* inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

PRMT5-MTA-IN-3-d3

PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

Host:	Mouse (3) Rabbit (1)
Reactivity:	Human (3) human (1)
Application:	IHC-P (1) ICC/IF (1) IP (1) WB (4) FC (3) ELISA (2)
Isotype:	IgG (1) IgG1 (1) IgG2b (2)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84536

	MTA1 Antibody (YA4233)	WB, FC, ELISA	Human
	MTA1 Antibody (YA4233) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to MTA1.

HY-P89655

	MTA3 Antibody (YA8999)	WB, IP	human
	MTA3 Antibody (YA8999) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MTA3.

HY-P84536A

	MTA1 Antibody (YA4233)(PBS only)	WB, FC, ELISA	Human
	MTA1 Antibody (YA4233) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to MTA1.

HY-P83599

	MTA2 Antibody (YA3344) Mata1l1; Metastasis associated gene 1 like 1; Metastasis associated gene family member 2; MMTA2; MTA1L1; p53 target protein in deacetylase complex; PID	WB, IHC-P, ICC/IF, FC	Human
	MTA2 Antibody (YA3344) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MTA2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks